- Home
- SRZN vs IVVD Comparison
SRZN vs IVVD Comparison
Compare SRZN & IVVD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SRZN
- IVVD
- Stock Information
- Founded
- SRZN 2015
- IVVD 2020
- Country
- SRZN United States
- IVVD United States
- Employees
- SRZN N/A
- IVVD N/A
- Industry
- SRZN Medicinal Chemicals and Botanical Products
- IVVD Biotechnology: Pharmaceutical Preparations
- Sector
- SRZN Health Care
- IVVD Health Care
- Exchange
- SRZN Nasdaq
- IVVD Nasdaq
- Market Cap
- SRZN 85.6M
- IVVD 96.7M
- IPO Year
- SRZN N/A
- IVVD 2021
- Fundamental
- Price
- SRZN $10.06
- IVVD $0.79
- Analyst Decision
- SRZN Strong Buy
- IVVD Strong Buy
- Analyst Count
- SRZN 2
- IVVD 3
- Target Price
- SRZN $38.50
- IVVD $5.85
- AVG Volume (30 Days)
- SRZN 13.7K
- IVVD 726.1K
- Earning Date
- SRZN 08-08-2025
- IVVD 08-18-2025
- Dividend Yield
- SRZN N/A
- IVVD N/A
- EPS Growth
- SRZN N/A
- IVVD N/A
- EPS
- SRZN N/A
- IVVD N/A
- Revenue
- SRZN $12,621,000.00
- IVVD $36,688,000.00
- Revenue This Year
- SRZN N/A
- IVVD $345.16
- Revenue Next Year
- SRZN N/A
- IVVD $161.08
- P/E Ratio
- SRZN N/A
- IVVD N/A
- Revenue Growth
- SRZN N/A
- IVVD N/A
- 52 Week Low
- SRZN $5.90
- IVVD $0.35
- 52 Week High
- SRZN $18.17
- IVVD $2.74
- Technical
- Relative Strength Index (RSI)
- SRZN 55.46
- IVVD 53.96
- Support Level
- SRZN $9.03
- IVVD $0.75
- Resistance Level
- SRZN $10.95
- IVVD $0.81
- Average True Range (ATR)
- SRZN 0.99
- IVVD 0.05
- MACD
- SRZN 0.03
- IVVD 0.00
- Stochastic Oscillator
- SRZN 44.88
- IVVD 65.69
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.